Bosulif and Hepatic function abnormal - a phase IV clinical study of FDA data

Summary:

Hepatic function abnormal is reported as a side effect among people who take Bosulif (bosutinib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Loperamide Hydrochloride, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Hepatic function abnormal when taking Bosulif. It is created by eHealthMe based on reports of 9,386 people who have side effects when taking Bosulif from the FDA, and is updated regularly.

What is Bosulif?

Bosulif has active ingredients of bosutinib. eHealthMe is studying from 9,401 Bosulif users. Check the latest studies of Bosulif.

What is Hepatic function abnormal?

Hepatic function abnormal is found to be associated with 1,436 drugs and 2,021 conditions by eHealthMe. Check the latest studies of Hepatic function abnormal.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

9,386 people reported to have side effects when taking Bosulif.
Among them, 28 people (0.3%) have Hepatic function abnormal.

Could Bosulif cause Hepatic function abnormal?

Among these 28 people:

How long have people been on Bosulif when they have Hepatic function abnormal? *

What is the gender of people who have Hepatic function abnormal when taking Bosulif? *

female: 64 %
male: 36 %

What is the age of people who have Hepatic function abnormal when taking Bosulif? *

What are other drugs people take besides Bosulif? *

Loperamide Hydrochloride: 5 people, 17.86%
Levofloxacin: 2 people, 7.14%
Amlodipine: 1 person, 3.57%
Buscopan: 1 person, 3.57%
Carvedilol: 1 person, 3.57%
Digoxin: 1 person, 3.57%
Dipyridamole: 1 person, 3.57%
Jakafi: 1 person, 3.57%
Jardiance: 1 person, 3.57%
Zofran: 1 person, 3.57%

What are other side effects people have besides Hepatic function abnormal? *

Diarrhea: 12 people, 42.86%
Rashes (redness): 7 people, 25.00%
C-Reactive Protein Increased: 5 people, 17.86%
Nausea And Vomiting: 3 people, 10.71%
Blood Uric Acid Increased: 3 people, 10.71%
Fever: 3 people, 10.71%
Upper Gastrointestinal Haemorrhage (upper gastrointestinal bleeding): 3 people, 10.71%
Nausea (feeling of having an urge to vomit): 3 people, 10.71%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 3 people, 10.71%
Erythema Multiforme (a type of hypersensitivity reaction): 3 people, 10.71%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 21 people, 75.00%
Diarrhea: 6 people, 21.43%
High Blood Pressure: 3 people, 10.71%
C-Reactive Protein Increased: 2 people, 7.14%
Type 2 Diabetes: 1 person, 3.57%
Neuralgia (pain in one or more nerves): 1 person, 3.57%
High Blood Cholesterol: 1 person, 3.57%
Dyslipidaemia (abnormal amount of lipids): 1 person, 3.57%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 3.57%
Bone Disorder: 1 person, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Bosulif and have Hepatic function abnormal?

- Check whether Hepatic function abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Bosulif:

Bosulif (9,401 reports)

Browse all side effects of Bosulif:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic function abnormal:

Hepatic function abnormal (1,436 drugs)

Browse all the conditions that are associated with Hepatic function abnormal:

Hepatic function abnormal (2,021 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bosutinib (the active ingredients of Bosulif) and Bosulif (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.